Reinhard Vonthein
University of Lübeck, University Hospital Schleswig-Holstein
Papers
2
Total Citations
22
H-Index
2
About
Reinhard Vonthein is a leading biostatistician whose work has profoundly shaped clinical trial methodology and evidence-based medicine, particularly in oncology. His primary research areas include the design and analysis of clinical trials, with a major focus on adaptive designs, sequential analysis, and the application of rigorous statistical methods to radiation oncology. Vonthein’s contributions are exemplified by his pivotal role in the HYPOSTAT trial, a landmark German prospective multicenter phase II study (ARO 2013-06) that established the safety and efficacy of hypofractionated robotic stereotactic body radiotherapy (SBRT) for localized prostate cancer. This work, culminating in a 2023 publication (6 citations), demonstrated that a highly condensed, non-invasive treatment schedule could achieve excellent tumor control with minimal side effects, directly challenging longer conventional fractionation regimens. Earlier, his 2017 feasibility trial (16 citations) laid the groundwork for this approach. Beyond these specific studies, Vonthein is renowned for his methodological innovations in adaptive trial designs, which allow for more efficient and ethical studies by modifying trial parameters based on accumulating data. His expertise ensures that complex clinical questions are answered with statistical rigor, making him an indispensable figure in translating cutting-edge therapies into standard care.
Research Focus
Key Achievements
Top Papers
- 1
- 2